Improvement of HAS-BLED bleeding score predictive capability by changing the definition of renal dysfunction in Japanese atrial fibrillation patients on anticoagulation therapy

Journal of Cardiology

Volumn 64, Issue 6, 2014, Pages 482-487

  Suzuki, Makoto ^a   Matsue, Yuya ^a   Nakamura, Rena ^a   Matsumura, Akihiko ^a   Hashimoto, Yuji ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Anticoagulation; Atrial fibrillation; Chronic kidney disease; Hemorrhagic complication; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSESSMENT; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HAS-BLED SCORE; HEART ATRIUM FIBRILLATION; HUMAN; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MAJOR HEMORRHAGIC EVENT; MALE; OUTCOME ASSESSMENT; RISK ASSESSMENT; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; EVALUATION STUDY; HEMORRHAGE; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FEMALE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84926406617     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.03.006     Document Type: Article

References (30)

1. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.Y., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann S., Smith S.C., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006, 48:854-906.
2. McNamara R.L., Tamariz L.J., Segal J.B., Bass E.B. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003, 139:1018-1033.
3. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
4. Go A.S., Fang M.C., Udaltsova N., Chang Y., Pomernacki N.K., Borowsky L., Singer D.E. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009, 119:1363-1369.
5. Vazquez E., Sanchez-Perales C., Borrego F., Garcia-Cortes M.J., Lozano C., Guzman M., Gil J.M., Borrego M.J., Perez V. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000, 140:886-890.
6. Bozbas H., Atar I., Yildirir A., Ozgul A., Uyar M., Ozdemir N., Muderrisoglu H., Ozin B. Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis. Ren Fail 2007, 29:331-339.
7. Genovesi S., Pogliani D., Faini A., Valsecchi M.G., Riva A., Stefani F., Acquistapace I., Stella A., Bonforte G., DeVecchi A., DeCristofaro V., Buccianti G., Vincenti A. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005, 46:897-902.
8. Limdi N.A., Beasley T.M., Baird M.F., Goldstein J.A., McGwin G., Arnett D.K., Acton R.T., Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009, 20:912-921.
9. Elliott M.J., Zimmerman D., Holden R.M. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007, 50:433-440.
10. McMahan D.A., Smith D.M., Carey M.A., Zhou X.H. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998, 13:311-316.
11. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Yamagata K., Tomino Y., Yokoyama H., Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
12. Rule A.D., Teo B.W. GFR estimation in Japan and China: what accounts for the difference?. Am J Kidney Dis 2009, 53:932-935.
13. Ogawa S., Aizawa Y., Atarashi H., Kamakura S., Koretsune Y., Kumagai K., Mitamura H., Okumura K., Sugi K., Yamashita T., Yasaka M., Hiejima K., Kodama I., Ohe T., Yano K. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 2010, 74:2479-2500.
14. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
15. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
16. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
17. Schulman S., Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3:692-694.
18. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
19. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
20. Nakagawa K., Hirai T., Takashima S., Fukuda N., Ohara K., Sasahara E., Taguchi Y., Dougu N., Nozawa T., Tanaka K., Inoue H. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol 2011, 107:912-916.
21. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:2599-2604.
22. Piccini J.P., Stevens S.R., Chang Y., Singer D.E., Lokhnygina Y., Go A.S., Patel M.R., Mahaffey K.W., Halperin J.L., Breithardt G., Hankey G.J., Hacke W., Becker R.C., Nessel C.C., Fox K.A., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013, 127:224-232.
23. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
24. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
25. Fox K.A., Piccini J.P., Wojdyla D., Becker R.C., Halperin J.L., Nessel C.C., Paolini J.F., Hankey G.J., Mahaffey K.W., Patel M.R., Singer D.E., Califf R.M. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
26. Shen A.Y., Yao J.F., Brar S.S., Jorgensen M.B., Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007, 50:309-315.
27. Fang M.C., Go A.S., Chang Y., Borowsky L.H., Pomernacki N.K., Udaltsova N., Singer D.E. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011, 58:395-401.
28. Gage B.F., Yan Y., Milligan P.E., Waterman A.D., Culverhouse R., Rich M.W., Radford M.J. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
29. Apostolakis S., Lane D.A., Guo Y., Buller H., Lip G.Y. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR 34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012, 60:861-867.
30. Roldan V., Marin F., Fernandez H., Manzano-Fernandez S., Gallego P., Valdes M., Vicente V., Lip G.Y. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013, 143:179-184.